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Multiple antibiotic reisistance threatens successful treat-
ment of Acinetobacter baumannii infections worldwide. In-
creasing interest in the well-known activity of sulbactam
against the genus Acinetobacter has been aroused. The purpose
of this study was to compare the outcomes for patients with
Acinetobacter bacteremia treated with cefoperazone/sulbactam
versus imipenem/cilastatin. Forty-seven patients with Acineto-
bacter baumannii bacteremia were analyzed through a retro-
spective review of their medical records for antibiotic therapy
and clinical outcome. Thirty-five patients were treated with
cefoperazone/sulbactam, and twelve patients with imipenem/
cilastatin. The percentage of favorable response after 72 hours
was not statistically different between cefoperazone/ sulbactam
group and imipenem/ cilastatin group. The mortality rate was
not statistically different, too. Cefoperazone/sulbactam was
found to be as useful as imipenem/cilastatin for treating
patients with Acinetobacter bacteremia.
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INTRODUCTION
Acinetobacter baumannii has emerged as an im-
portant nosocomial pathogen, and its multiple
antibiotic resistance threatens the successful treat-
ment of A. baumannii infections worldwide.1
Nowadays, most nosocomial isolates are resistant
to a wide variety of antibiotics, leaving carba-
penems as one of the only recognized therapeutic
alternative.2,3 In this setting, the overuse of imi-
penem has been associated with reports of several
outbreaks caused by carbapenem-resistant strains,
often leaving polymyxin and sulbactam as the
only antibiotics with in vitro activity against these
organisms.2,4 Moreover, resistance to imipenem is
becoming more common.5 Therapy in such cases
is a serious challenge, and consequently, the well-
known activity of sulbactam against the genus
Acinetobacter is receiving renewed attention.6
In one study, the authors reported that sul-
bactam might prove effective in non-life-threat-
ening A. baumannii infections.2 In another study,
the authors found ampicillin-sulbactam to be
effective in the treatment of a small number of
patients with Acinetobacter ventilator-associated
pneumonia.
7
However, to our knowledge no
reports have been issued about the efficacy of
cefoperazone/sulbactam for the treatment of
Acinetobacter bacteremia.
The purpose of this study was to compare the
outcomes of patients with Acinetobacter bacte-
remia who were treated with cefoperazone/
sulbactam or imipenem-cilastatin.
MATERIALS AND METHODS
Study population
We reviewed the records of the clinical micro-
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biology laboratory and identified patients with
significant bacteremia caused by A. baumannii,
who registered between 1998 and 2002 at the
Severance Hospital, Yonsei University College of
Medicine, retrospectively. Demographic, clinical,
and microbiological data were extracted from the
patients' medical records.
Identification and antimicrobial susceptibility
testing
CLSIThe isolates were identified using conven-
tional techniques and/or ATB 32 GN system
(bioMerieux, Marcy-l'Etoile, France).8 The antimi-
crobial susceptibilities of Acinetobacter isolates
were determined by microbiology laboratory staff
using a disk-diffusion method. Results were in-
terpreted using the guidelines established by the
Clinical and Laboratory Standards Institute (CLSI),
formerly the National Committee for Clinical
Laboratory Standards (NCCLS).9 The cefopera-
zone/sulbactam susceptibility of Acinetobacter was
determined using a disk containing 75 g ofμ
cefoperazone and 30 g of sulbactam. The zoneμ
diameter used for cefoperazone in the CLSI
guideline was used for cefoperazone/sulbactam.
Intermediate susceptibility to the antibiotics was
considered as resistance.
Definitions
‘Significant bacteremia’ was defined as the
isolation of bacterial species from one or more
blood cultures, and by the presence of signs
responsible for sepsis. Standard Center for Disease
Control nosocomial infection definitions were
used to define the sites of infection.10 Bacteremia
was considered 'nosocomial' if (a) a positive blood
culture was obtained after 72 h of admission and
there was no evidence of infection at the time of
admission; or if (b) infections were acquired at
other hospitals before transfer to the study hos-
pital; or if (c) infections were acquired during a
previous admission within 2 weeks of presenta-
tion. Otherwise, the bacteremia was considered to
be community-acquired. The initial empirical anti-
microbial therapy was considered appropriate if
the initial antibiotics, which were administered
within 24 h after acquisition of a blood culture
samples, included at least one antibiotic that was
active in vitro against the causative microor-
ganisms and when the dosage and route of admi-
nistration conformed with current medical stan-
dards.11 Inappropriate initial antimicrobial therapy
referred to the administration of antimicrobial
agents to which the causative microorganisms
were resistant in vitro or to the lack of an antimi-
crobial therapy for a known causative pathogen.
If the antimicrobial agent was not administered
within 24 h of bacteremia onset, antimicrobial use
was considered inappropriate. Disease severity
was scored using the APACHE II system.
Antibiotic therapy and outcome
Empiric antibiotic therapy was initiated imme-
diately after a blood culture had been performed.
In most patients, an antipseudomonal -lactamβ
antimicrobial agent (piperacillin/tazobactam,
ceftazidime, cefoperazone/sulbactam, imipenem/
cilastatin, or meropenem) was administered as an
empiric therapy. Empiric antibiotic therapy was
changed to definitive therapy, as needed, on the
basis of the results of culture and sensitivity
testing. The choice of definitive therapy was made
at the discretion of the attending physician, but
imipenem/cilastatin generally was used for
imipenem-susceptible Acinetobacter isolates. Cefo-
perazone/sulbactam generally was used for
cefoperazone-susceptible isolates. Use of vanco-
mycin or aminoglycoside was done at the discre-
tion of the attending physician but was not
routine. The evaluation of efficacy was based on
the clinical response to therapy. Clinical outcomes
were analyzed using; outcomes after 72 hrs of
treatment, 7-day mortality and 30-day mortality.
Clinical outcomes after 72 hrs of treatment were
categorized as complete response, partial re-
sponse, failure, or death. ‘Complete response’
was defined as the eradication of all presenting
signs and symptoms of infection, and ‘partial
response’ as the resolution of some but not all of
these signs and symptoms. Treatment was con-
sidered a ‘failure’ if these signs and symptoms
did not improve appreciably. ‘Death’ was de-
fined as a death within 72 hrs of initiating treat-
ment. Complete response and partial response
were considered favorable response, and failure
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and death were considered unfavorable response.
Statistical analysis
Discrete variables were compared between
groups using Fisher's exact test or χ2 statistics, as
appropriate. Continuous variables were compared
using the Student's t-test. A p-value of < 0.05 was
considered statistically significant. The SPSS (ver-
sion 11.0) software package was used for all
analyses.
RESULTS
Demographic and clinical characteristics
A total of 72 patients with significant Acineto-
bacter bacteremia were identified, and of these, 47
patients were treated with cefoperazone/sul-
bactam or imipenem/cilastatin as a definitive
treatment regimen. Thirty-five patients with
Acinetobacter bacteremia were treated with cefo-
perazone/sulbactam, and 12 patients were treated
with imipenem/cilastatin. The clinical charac-
teristics of patients treated with cefoperazone/
sulbactam or imipenem/cilastatin are sum-
marized in Table 1. The baseline characteristics of
the patients in the treatment groups were statis-
tically similar. Most isolates (97.9%) were noso-
comial pathogen. The common sites of primary
infection were the lungs (pneumonia), intravas-
cular catheter related infection, and biliary tract
infection. There was a higher incidence of pneu-
monia among patients in the imipenem/cilastatin
group.
Table 1. Demographic Characteristics of Patients with Acinetobacter Bacteremia Treated with Cefoperazone/sulbactam
or Imipenem/cilastatin
Parameters Cefoperazone/sulbactam (n = 35) Imipenem/cilastatin (n = 12) p value
Age, mean years ± SD 45 ± 28 55 ± 23 0.280
Sex, No. of male/No. of female 24/11 8/4 1.000
APACHE II score, mean ± SD 12.52 ± 5.38 13.86 ± 5.42 0.566
Aminoglycoside use (%) 65.7% 58.3% 0.733
Underlying disease (No. of cases)
Solid tumor 12 5 0.733
Heart failure 6 2 1.000
Intracranial hemorrhage 4 2 0.637
Diabetes Mellitus 1 2 0.156
Liver cirrhosis 1 1 0.450
Leukemia 2 0 1.000
Benign biliary tract disease 2 0 1.000
Autoimmune disease 1 0 1.000
Hemophagocytic syndrome 1 1 0.450
End stage renal disease 2 0 1.000
Multiple myeloma 1 0 1.000
Site of primary infection (No. of cases)
Pneumonia 15 10 0.020
IV catheter related infection 9 0 0.087
Biliary tract infection 4 2 0.637
Primary blood stream infection 4 0 0.560
Urinary tract infection 2 0 1.000
Wound infection 1 0 1.000
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Antimicrobial susceptibility patterns and antimi-
crobial therapy
Regarding antimicrobial susceptibility, all epi-
sodes of bacteremia in the imipenem/cilastatin
group were caused by isolates that were fully
susceptible to imipenem/cilastatin. Two isolates
in imipenem/cilastatin group were resistant to
cefoperazone/sulbactam. Of the 35 patients that
were treated with cefoperazone/sulbactam, 2
were fully resistant to imipenem/cilastatin, 2 were
intermediately resistant, and 31 were susceptible.
All isolates in cefoperazone/sulbactam group
were susceptible to cefoperazone/sulbactam. All
definite antimicrobial therapies were‘appropriate’
antimicrobial therapy. Empiric antimicrobial ther-
apies were ‘appropriate’ in 29 patients and ‘in-
appropriate’ in 18 patients. Appropriateness of
empiric antimicrobial therapy was not associated
with clinical outcomes such as outcomes after 72
hrs of treatment, 7-day mortality and 30-day
mortality.
Clinical responses at 72 hours according to
antibiotic treatment
Clinical responses at 72 hours after antibiotic
treatment are listed versus the definite antibiotic
treatment regimens in Table 2.
The percentage of complete and partial re-
sponse was not statistically different (77% for the
cefoperazone/sulbactam group vs. 75% for the
imipenem/cilastatin group; p = 1.000).
In the subgroup of pneumonia patients, the
percentage of complete and partial response was
not statistically different between cefoperazone/
sulbactam group and imipenem/cilastatin group
(60% for the cefoperazone/sulbactam group vs.
80% for the imipenem/cilastatin group; p=0.402).
Mortality according to antibiotic treatment
The mortalities of the patients with Acine-
tobacter bacteremia are listed with their respective
antibiotic treatment regimens in Table 3. The 7-
Table 2. Clinical Response at 72 Hours According to Definite Antibiotic Treatment Regimens
Response Cefoperazone/sulbactam (n = 35) Imipenem/cilastatin (n = 12) p value
Overall 1.000
Favorable response 27/35 (77.1%) 9/12 (75.0%)
Unfavorable response 8/35 (22.9%) 3/12 (25.0%)
Pneumonia 0.402
Favorable response 9/15 (60.0%) 8/10 (80.0%)
Unfavorable response 6/15 (40.0%) 2/10 (20.0%)
Biliary tract infection 0.333
Favorable response 4/4 (100%) 1/2 (50.0%)
Unfavorable response 0/4 (0%) 1/2 (50.0%)
IV catheter related infection
Favorable response 7/9 (77.8%) - -
Unfavorable response 2/9 (22.2%) - -
Primary blood stream infection
Favorable response 4/4 (100%) - -
Unfavorable response 0/4 (0%) - -
Urinary tract infection
Favorable response 2/2 (100%) - -
Unfavorable response 0/2 (0%) - -
Wound infection
Favorable response 1/1 (100%) - -
Unfavorable response 0/1 (0%) - -
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day mortality rate was lower in the cefoperazone/
sulbactam group than in imipenem/cilastatin
group, but this was not statistically significant
(17.1% for cefoperazone/sulbactam group vs.
33.3% for imipenem/cilastatin group, p = 0.251).
Thirty-day mortality rate was also lower in the
cefoperazone/sulbactam group than in the imi-
penem/cilastatin group, but again this was not
significant (20.0% for the cefoperazone/sulbactam
group vs. 50.0% for the imipenem/cilastatin
group, p = 0.065).
DISCUSSION
Over the last 20 years, A. baumannii has
emerged as an important nosocomial pathogen.
However, the treatment of choice for A. baumannii
bacteremia has not been established. There have
been no comparative therapeutic trials, and clini-
cal experience is lacking. The usual treatment is
an active -lactam alone or in association with anβ
aminoglycoside, which is similar to the treatment
of bacteremia caused by other Gram-negative
bacilli.3,12 A general trend towards decreased
susceptibility to antibiotics has been observed
worldwide in the majority of nosocomial strains.
Multiple antibiotic resistance threatens the suc-
cessful treatment of A. baumannii infections world-
wide. Nowadays, most nosocomial isolates are
resistant to the variety of antibiotics tested rou-
tinely, leaving carbapenems, mainly imipenem, as
almost the only recognized therapeutic alterna-
tive. Imipenem treatment resulted in a cure for
bacteremia in 83% of the cases in one study.4
However, the overuse of imipenem has been
associated with several outbreaks of carbapenem-
resistant strains, often leaving polymyxin and
sulbactam as the only antibiotics with in-vitro
activity against these organisms.4
Sulbactam is an inhibitor of -lactamase, whichβ
shows in vitro bactericidal activity against
Table 3. Treatment Outcomes According to the Sites of Primary Infection and Antibiotic Treatment Regimens
Outcome Cefoperazone/sulbactam (n = 35) Imipenem/cilastatin (n = 12) p value
Overall
7 days mortality 6/35 (17.1%) 4/12 (33.3%) 0.251
30 days mortality 7/35 (20.0%) 6/12 (50.0%) 0.065
Pneumonia
7 days mortality 5/15 (33.3%) 3/10 (30.0%) 1.000
30 days mortality 6/15 (40.0%) 5/10 (50.0%) 0.697
Biliary tract infection
7 days mortality 0/4 (0.0%) 1/2 (50.0%) 0.333
30 days mortality 0/4 (0.0%) 1/2 (50.0%) 0.333
IV catheter related infection
7 days mortality 1/9 (11.1%) - -
30 days mortality 1/9 (11.1%) - -
Primary blood stream infection
7 days mortality 0/4 (0.0%) - -
30 days mortality 0/4 (0.0%) - -
Urinary tract infection
7 days mortality 0/2 (0.0%) - -
30 days mortality 0/2 (0.0%) - -
Wound infection
7 days mortality 0/1 (0.0%) - -
30 days mortality 0/1 (0.0%) - -
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Acinetobacter sp.13,14 Rodriquez-Hernandez et al.15
showed that the efficacy of sulbactam in experi-
mental infections caused by susceptible A.
baumannii strains is similar to that of imipenem.
Corbella et al.2 treated 42 patents with non-life-
threatening multiresistant A. baumannii infections,
including seven bacteremias, with sulbactam
alone and in combination with ampicillin; 39
improved or were cured with no major adverse
affect. Ampicillin-sulbactam was found to be at
least as effective as imipenem and a cost-effective
alternative for the treatment of non-life-threat-
ening multiresistant A. baumannii infections.16
Wood et al.7 reported that ampicillin-sulbactam
was effective at treating a small number of
patients with Acinetobacter ventilator-associated
pneumonia.
Studies in North America, South America,
Europe and Asia have investigated the in vitro
activity of cefoperazone-sulbactam, and have
shown it to be superior to that of cefoperazone
alone against clinical isolates of many Gram-neg-
ative bacilli, but particularly against Acinetobacter
species, in which activity is due to sulbactam
alone.6,17-21 However, the efficacy of cefoperazone/
sulbactam against Acinetobacter has not been
studied in a clinical setting.
The results of the present study show that
cefoperazone/sulbactam appears to be useful for
the treatment of Acinetobacter bacteremia. These
results suggest that sulbactam could be used for
the treatment of life threatening infections by A.
baumanni, and suggest that not only ampicillin/
sulbactam but also cefoperazone/sulbactam could
be used for the treatment of infections by A.
baumannii. These results are encouraging because
of the potential for high mortality in cases of
Acinetobacter infection given increasing imipenem
resistance among Acinetobacter isolates and the
lack of treatment options.
17,22
One of the most important problems associated
with previous studies upon the in vitro activity of
cefoperazone/sulbactam against Acinetobacter con-
cerns the different criteria used to define sus-
ceptibility. In the case of the cefoperazone/sul-
bactam combination, there is no CLSI standard
sulbactam concentration for the agar dilution or
disk diffusion tests, and interpretations usually
take into account the MICs of cefoperazone. In
vitro studies have shown that cefoperazone/
sulbactam is more active than a variety of
individual -lactam agents againstβ Acinetobacter
species, and only imipenem has demonstrated in
vitro activity superior to that of cefoperazone-
sulbactam.23,24 A standard method for the evalua-
tion of the sensitivity of Acinetobacter to cefo-
perazone/sulbactam is needed.
Unfortunately, resistance to sulbactam has been
noted in imipenem-resistant strains of A.
baumannii, leaving the polymyxin as the only
treatment alternative.12,25 Levin et al.26 reported
upon the outcomes of 60 nosocomial infections,
including bacteremia, caused by A. baumannii and
Pseudomonas aeruginosa, which were resistant to all
commercially available antimicrobial agents.
These infections were treated with colistin, but
colistin causes some critical adverse effects, such
as nephrotoxicity or neurotoxicity.
The several potential limitations of the present
study include its retrospective design, the small
number of patients, and potential differences
between the groups, which may have favored the
use of cefoperazone/sulbactam or imipenem/
cilastatin.
In summary, cefoperazone/sulbactam was
found to be as useful as imipenem/cilastatin for
the treatment of Acinetobacter bacteremia in a
small number of patients. Prospective study should
be undertaken upon the efficacy of cefoperazone/
sulbactam for the treatment of patients with
Acinetobacter bacteremia.
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